Ossiam Has $18.15 Million Stock Holdings in DexCom, Inc. $DXCM

Ossiam grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 22.0% during the third quarter, HoldingsChannel.com reports. The firm owned 269,700 shares of the medical device company’s stock after buying an additional 48,560 shares during the period. Ossiam’s holdings in DexCom were worth $18,148,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of DexCom by 2.3% during the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after purchasing an additional 1,133,638 shares during the period. Geode Capital Management LLC lifted its stake in DexCom by 3.4% in the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after buying an additional 358,617 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock worth $576,610,000 after buying an additional 3,410,858 shares during the last quarter. Norges Bank acquired a new position in shares of DexCom during the 2nd quarter worth about $453,279,000. Finally, Groupama Asset Managment grew its position in shares of DexCom by 79,043.1% during the 2nd quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after buying an additional 4,011,438 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Citigroup increased their price target on shares of DexCom from $77.00 to $84.00 and gave the company a “buy” rating in a research report on Wednesday. Evercore started coverage on shares of DexCom in a report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price on shares of DexCom in a research note on Monday, March 9th. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Finally, Barclays reissued an “underweight” rating and set a $72.00 price target (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $85.50.

DexCom Price Performance

Shares of DXCM opened at $64.24 on Friday. The stock has a 50 day simple moving average of $70.66 and a 200 day simple moving average of $68.45. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The firm has a market capitalization of $24.72 billion, a PE ratio of 30.59, a P/E/G ratio of 1.27 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The firm had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s revenue was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.45 earnings per share. Sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.